Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | PRLHR | P49683 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | TFPI | P10646 | 4/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC1R | Q01726 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26292602 | 0.95 | RAMP3 (0.49) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26305035 | 0.95 | NPY2R (0.47) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29311844 | 0.93 | APLNR (0.43) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26292629 | 0.93 | RAMP3 (0.47) | CTNNB1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL26292620 | 0.93 | RAMP3 (0.47) | CTNNB1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL29311757 | 0.91 | CSNK2A2 (0.43) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29311547 | 0.91 | CSNK2A2 (0.43) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29311858 | 0.91 | KCNA3 (0.43) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26292635 | 0.91 | RAMP3 (0.46) | NPY2RCTNNB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29311618 | 0.91 | CSNK2A2 (0.46) | NPY2RCSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | NPY2R 602/4885CTNNB1 3039/4885CSNK2A2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.